Santhera Pharmaceuticals Holding AG (SPHDF)

[beebob77]

SPHDF is one step ahead in DMD submission!

Check out Santhera Pharm with a 100 - 400% opportunity:
In comparision to the peers PTC or SRPT we have a fair value of 180USD/share without NDA submission.

Expected Upcoming Milestones
Q4 2014 – Start Phase I CALLISTO study for omigapil in CMD.
H1 2015 – CHMP decision on Raxone as an LHON treatment.
H1 2015 – NDA and MAA submission for Raxone/Catena as a DMD treatment.
H1 2015 – NDA submission for Raxone/Catena for LHON.
H2 2015 – Commercial launch of Raxone for LHON in EU.
Q1 2016 – Commercial launch of Raxone/Catena for DMD in US and EU.
H1 2016 – Commercial launch of Raxone/Catena for LHON in US.


DMD - Market Opportunity
The various price points are, on average, between $300,000 and $500,000 per patient per year. If you consider this in terms of the target population, the company estimates there would be about 2,000 patients in the U.S. that would be amenable to Eteplirsen. This translates into a $600 million to $1 billion market opportunity in the U.S. alone. The EU could add 9,000 additional patients as well.

LifeSci Capital Coverage: link

ValualationLAB Analysis: link